Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

被引：0
作者：
Seiichi Okabe
Tetsuzo Tauchi
Yuko Tanaka
Kazuma Ohyashiki
机构：
[1] Tokyo Medical University,First Department of Internal Medicine
来源：
Journal of Hematology & Oncology | / 4卷
关键词：
Imatinib; Chronic Myeloid Leukemia; Dasatinib; Nilotinib; Chronic Myeloid Leukemia Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilotinib-resistant cell line, K562NR, and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel therapy for CML.
引用
收藏
相关论文
共 50 条
  • [41] CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation
    Fang, Zhenghuan
    Jung, Kyung Hee
    Yan, Hong Hua
    Kim, Soo Jung
    Son, Mi Kwon
    Rumman, Marufa
    Lee, Hyunseung
    Kim, Ki Woon
    Yoo, Hye-Dong
    Hong, Soon-Sun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) : 253 - 261
  • [42] Tyrosine kinase inhibitor Thiotanib targets Bcr-Abl and induces apoptosis and autophagy in human chronic myeloid leukemia cells
    Jiajun Fan
    Xiaochun Dong
    Weixing Zhang
    Xian Zeng
    Yubin Li
    Yun Sun
    Shaofei Wang
    Ziyu Wang
    Hongjian Gao
    Weili Zhao
    Dianwen Ju
    Applied Microbiology and Biotechnology, 2014, 98 : 9763 - 9775
  • [43] Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?
    Eskazan, Ahmet Emre
    Soysal, Teoman
    Erbilgin, Yucel
    Ozbek, Ugur
    Ferhanoglu, Burhan
    LEUKEMIA RESEARCH, 2011, 35 (09) : E145 - E146
  • [44] ALTERED APOPTOTIC PROTEIN EXPRESSIONS CHARACTERIZE THE SURVIVAL OF BCR-ABL-INDEPENDENT DRUG-RESISTANT CHRONIC MYELOID LEUKEMIA CELL LINE
    Baykal-Kose, Seda
    Yalcin, Pelin
    JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, 2021, 5 (01): : 1 - 5
  • [45] Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia
    Shimoni, A.
    Leiba, M.
    Schleuning, M.
    Martineau, G.
    Renaud, M.
    Koren-Michowitz, M.
    Ribakovski, E.
    le Coutre, P.
    Arnold, R.
    Guilhot, F.
    Nagler, A.
    LEUKEMIA, 2009, 23 (01) : 190 - 194
  • [46] The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
    Lange, Thoralf
    Ernst, Thomas
    Gruber, Franz X.
    Maier, Jacqueline
    Cross, Michael
    Mueller, Martin C.
    Niederwieser, Dietger
    Hochhaus, Andreas
    Pfirrmann, Markus
    HAEMATOLOGICA, 2013, 98 (05) : 714 - 717
  • [47] Betanin a betacyanin pigment purified from fruits of Opuntia ficus-indica induces apoptosis in human chronic myeloid leukemia Cell line-K562
    Sreekanth, Devalraju
    Arunasree, M. K.
    Roy, Karnati R.
    Reddy, T. Chandramohan
    Reddy, Grorla V.
    Reddanna, Pallu
    PHYTOMEDICINE, 2007, 14 (11) : 739 - 746
  • [48] Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy
    Willig, Julia Biz
    de Couto, Nadia Mileo Garces
    Vianna, Debora Renz Barreto
    Mariot, Camila da Silveira
    Gnoatto, Simone Cristina Baggio
    Buffon, Andreia
    Pilger, Diogo Andre
    PHARMACEUTICALS, 2023, 16 (04)
  • [49] Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
    Breccia, Massimo
    Mauro, Michael
    Jabbour, Elias
    Saglio, Giuseppe
    Jimenez-Velasco, Antonio
    le Coutre, Philipp
    DeGutis, Irene
    Khan, Wasiulla
    Sy, Oumar
    Swanink, Rene
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S326 - S327
  • [50] Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model
    Park, Juwon
    Kim, Kyung Im
    Koh, Youngil
    Won, Nam-Hee
    Oh, Jung Mi
    Lee, Dong Soon
    Kim, Byoung Kook
    Ahn, Kwang-Sung
    Yoon, Sung-Soo
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : 773 - 781
12345